Zacks: ContraFect Corp (CFRX) Given $2.63 Consensus Price Target by Brokerages
Shares of ContraFect Corp (NASDAQ:CFRX) have been given a consensus broker rating score of 1.00 (Strong Buy) from the four analysts that provide coverage for the stock, Zacks Investment Research reports. Four analysts have rated the stock with a strong buy rating.
Brokerages have set a 12 month consensus target price of $2.63 for the company and are anticipating that the company will post ($0.11) earnings per share for the current quarter, according to Zacks. Zacks has also given ContraFect an industry rank of 43 out of 255 based on the ratings given to its competitors.
Institutional investors and hedge funds have recently modified their holdings of the company. Hartwell J M Limited Partnership boosted its position in ContraFect by 150.0% during the 1st quarter. Hartwell J M Limited Partnership now owns 100,000 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 60,000 shares during the period. Geode Capital Management LLC raised its holdings in ContraFect by 8.3% in the 4th quarter. Geode Capital Management LLC now owns 377,908 shares of the biotechnology company’s stock valued at $578,000 after acquiring an additional 29,009 shares in the last quarter. White Pine Capital LLC raised its holdings in ContraFect by 24.9% in the 4th quarter. White Pine Capital LLC now owns 294,730 shares of the biotechnology company’s stock valued at $451,000 after acquiring an additional 58,725 shares in the last quarter. Northern Trust Corp boosted its position in shares of ContraFect by 46.5% in the fourth quarter. Northern Trust Corp now owns 114,131 shares of the biotechnology company’s stock worth $175,000 after purchasing an additional 36,239 shares during the period. Finally, Trellus Management Company LLC boosted its position in shares of ContraFect by 43.7% in the fourth quarter. Trellus Management Company LLC now owns 120,676 shares of the biotechnology company’s stock worth $185,000 after purchasing an additional 36,721 shares during the period. Institutional investors own 55.57% of the company’s stock.
ContraFect (NASDAQ:CFRX) last issued its earnings results on Thursday, March 14th. The biotechnology company reported $0.07 EPS for the quarter, topping the consensus estimate of ($0.10) by $0.17. Equities research analysts anticipate that ContraFect will post -0.38 EPS for the current fiscal year.
ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that is in Phase II human clinical trials for the treatment of Staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic varieties of human influenza.
Featured Story: How to Profit and Limit Losses With Stop Orders
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ContraFect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect and related companies with MarketBeat.com's FREE daily email newsletter.